KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.95

Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age.

Adam S Faye, David T Rubin, Corey A Siegel, Millie D Long, Nabeel Khan, Silvio Danese, Peter M Irving, Raymond K Cross, Irina Blumenstein, Alessandro Armuzzi, Sara N Horst, Axel Dignass, Taku Kobayashi, Garrett Lawlor, Anthony Krakovich, AnnKatrin Petersen, Zhaohui Liu, Dong Wang, Anjali Jain, Ashwin N Ananthakrishnan, João Sabino

Inflamm Bowel Dis 32(3) 512-525

PMID41274280
PMCIDPMC12794806
DOI10.1093/ibd/izaf258
发表日期2025-11-22
入排依据:Study is a Phase III randomized trial of a drug for ulcerative colitis (non-oncology). No time-to-event oncology endpoint (e.g., OS, PFS) is reported in the abstract; endpoints are clinical response rates (efficacy rates) and safety.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:非 KM 图;Figure 3.:非 KM 图。
摘要

摘要

BACKGROUND: Older adults with ulcerative colitis (UC) have unique treatment challenges. Ozanimod is approved for the treatment of moderately to severely active UC in adults based on the phase 3 True North (TN) study results. Here, we analyzed the impact of patient age on ozanimod safety and efficacy in TN and during the open-label extension (OLE). METHODS: Patients were stratified by age at TN baseline: <40, 40 to 60, and >60 years (cutoff: 75 years). Safety was evaluated in all patients during TN and the OLE; efficacy was assessed at weeks 10 and 52 in TN and up to OLE week 190 in patients who entered as TN week 52 ozanimod clinical responders. RESULTS: Of 1012 patients analyzed, 492 were <40 years of age, 404 were 40 to 60 years of age, and 116 were >60 years of age. Infection, malignancy, cardiac events, and macular edema were low throughout TN across all ages. Exposure-adjusted incidence rates (EAIRs) of opportunistic and serious infections increased with age during the OLE. Patients ≥40 years of age had higher hypertension EAIRs than those <40 years of age, but EAIRs of other cardiovascular TEAEs were low. No cases of progressive multifocal leukoencephalopathy occurred over 242 weeks of ozanimod exposure. Efficacy rates for evaluated clinical and mucosal endpoints at weeks 10 and 52 with ozanimod were generally consistent across age groups with the overall population; similar trends were observed in the OLE. CONCLUSIONS: Ozanimod safety was similar and efficacy was generally comparable across age groups, although statistical significance vs placebo was not achieved in patients >60 years of age.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Efficacy during the induction period by age group. (A) Clinical remission. (B) Clinical response. (C) Endoscopic improvement. (D) Histologic remission. (E) Mucosal healing. Treatment differences (Δ), 2-sided Wald confidence intervals (CIs), and P values for comparison between ozanimod and placebo (cohort 1) are based on the Cochran-Mantel-Haenszel test, stratified by corticosteroid use at screening and prior anti–tumor necrosis factor use. aRectal bleeding subscore (RBS) = 0, stool frequency subscore ≤1 (and a decrease of ≥1 point from baseline stool frequency subscore), and Mayo endoscopy subscore (MES) ≤1. bReduction from baseline in the 9-point Mayo score of ≥2 points and ≥35%, and a reduction from baseline in RBS of ≥1 point or an absolute RBS ≤1. cMES ≤1 without friability. dGeboes score <2.0. eMES ≤1 and Geboes score <2.0. * P < 0.05. ** P < 0.01. *** P < 0.001.
非 KM Figure
Figure 2.Efficacy during the maintenance period by age group. (A) Clinical remission. (B) Clinical response. (C) Endoscopic improvement. (D) Histologic remission. (E) Mucosal healing. (F) Corticosteroid-free remission. Treatment differences (Δ), 2-sided Wald confidence intervals (CIs), and P values for comparison between ozanimod/ozanimod vs ozanimod/placebo are based on the Cochran-Mantel-Haenszel test, stratified by CS use and remission status at week 10. aRectal bleeding subscore (RBS) = 0, stool frequency subscore ≤1 (and a decrease of ≥1 point from baseline stool frequency subscore), and Mayo endoscopy subscore (MES) ≤1. bReduction from baseline in the 9-point Mayo score of ≥2 points and ≥35%, and a reduction from baseline in RBS of ≥1 point or an absolute RBS ≤1. cMES ≤1 without friability. dGeboes score <2.0. eMES ≤1 and Geboes score <2.0. fClinical remission without CS use for ≥12 weeks. * P < 0.05. *** P < 0.001. CS, corticosteroid.
非 KM Figure
Figure 3.Long-term efficacy during the open-label extension (OLE) by age group in patients receiving continuous ozanimod who entered the OLE in clinical response at True North week 52. (A) Observed case (OC) analysis. (B) Nonresponder imputation (NRI) used for missing data. aRectal bleeding subscore (RBS) = 0, stool frequency subscore ≤1 (and a decrease of ≥1 point from baseline), and Mayo endoscopy subscore (MES) ≤1. bReduction from baseline in 9-point Mayo score of ≥2 points and ≥35%, and reduction from baseline in RBS of ≥1 point or absolute RBS ≤1. cMES ≤1 without friability. dClinical remission while off CS for ≥12 weeks. eGeboes score <2.0. fMES ≤1 and Geboes score <2.0. CS, corticosteroid.
非 KM Figure